Advertisement

Possible Association Between 3,4-Methylenedioxymethamphetamine Abuse and Valvular Heart Disease

      Valvular heart disease, inducing valvular regurgitation, has been described in users of drugs such as anorectic agents and ergot derivates. 3,4-Methylenedioxymethamphetamine (MDMA; “ecstasy”) also leads in vitro to the proliferation of cardiac valvular interstitial cells by activation of the 5-hydroxytryptamine 2B receptor. The aim of this study was to determine the occurrence of valvulopathy in young adults taking MDMA. Twenty-nine subjects using or having used MDMA and 29 gender- and age-matched controls were blindly evaluated with echocardiography. Eight subjects (28%) who took MDMA had abnormal echocardiographic results using the United States Food and Drug Administration’s criteria for appetite suppressant–induced valvular heart disease, compared with none in the control group (p = 0.0045). Six (21%) subjects had mitral regurgitation of 1/4 and 4 (14%) of ≥2/4, compared with none in the control group (p = 0.002). The mean mitral regurgitant area ratios (jet/atrium) were 12 ± 9.8% and 5 ± 1.3%, respectively (p = 0.007). Tricuspid regurgitation ≥2/4 was present in 13 MDMA users (45%) and absent in controls (p <0.001). The mean tricuspid regurgitant area ratios were 19 ± 9.5% and 9 ± 4.5%, respectively (p <0.001). Four MDMA users (14%) had mild aortic regurgitation (p = 0.11). Valvular “strands” were present in 6 MDMA users (21%) and in none of the controls (p = 0.02). In conclusion, MDMA may lead to mild to moderate valvular heart disease and valvular strands.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Setola V.
        • Hufeisen S.J.
        • Grande-Allen K.J.
        • Vesely I.
        • Glennon R.A.
        • Blough B.
        • Rothman R.B.
        • Roth B.L.
        3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro.
        Mol Pharmacol. 2003; 63: 1223-1229
      1. European Monitoring Centre for Drugs and Drug Addiction. Annual report 2005: the state of the drugs problem in Europe. Available at: http://annualreport.emcdda.eu.int. Accessed July 20, 2006.

      2. Multidisciplinary Association for Psychedelic Studies. MDMA research information: clinical research. Available at: http://www.maps.org/mdma/#clinical. Accessed June 20, 2006.

        • Zoghbi W.A.
        • Enriquez-Sarano M.
        • Foster E.
        • Grayburn P.A.
        • Kraft C.D.
        • Levine R.A.
        • Nihoyannopoulos P.
        • Otto C.M.
        • Quinones M.A.
        • Rakowski H.
        • et al.
        Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography.
        J Am Soc Echocardiogr. 2003; 16: 777-802
        • Singh J.P.
        • Evans J.C.
        • Levy D.
        • Larson M.G.
        • Freed L.A.
        • Fuller D.L.
        • Lehman B.
        • Benjamin E.J.
        Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study).
        Am J Cardiol. 1999; 83: 897-902
      3. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997.
        Morbid Mortal Wkly Rep. 1997; 46: 1061-1066
        • Van Camp G.
        • Flamez A.
        • Cosyns B.
        • Weytjens C.
        • Muyldermans L.
        • Van Zandijcke M.
        • De Sutter J.
        • Santens P.
        • Decoodt P.
        • Moerman C.
        • Schoors D.
        Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease.
        Lancet. 2004; 363: 1179-1183
        • Zanettini R.
        • Antonini A.
        • Gatto G.
        • Gentile R.
        • Tesei S.
        • Pezzoli G.
        Valvular heart disease and the use of dopamine agonists for Parkinson’s disease.
        N Engl J Med. 2007; 356: 39-46
        • Schade R.
        • Andersohn F.
        • Suissa S.
        • Haverkamp W.
        • Garbe E.
        Dopamine agonists and the risk of cardiac-valve regurgitation.
        N Engl J Med. 2007; 356: 29-38
        • Fitzgerald L.W.
        • Burn T.C.
        • Brown B.S.
        • Patterson J.P.
        • Corjay M.H.
        • Valentine P.A.
        • Sun J.H.
        • Link J.R.
        • Abbaszade I.
        • Hollis J.M.
        • et al.
        Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine.
        Mol Pharmacol. 2000; 57: 75-81
        • Freedberg R.S.
        • Goodkin G.M.
        • Perez J.L.
        • Tunick P.A.
        • Kronzon I.
        Valve strands are strongly associated with systemic embolization: a transesophageal echocardiographic study.
        J Am Coll Cardiol. 1995; 26: 1709-1712
        • Nighoghossian N.
        • Derex L.
        • Perinetti M.
        • Honnorat J.
        • Barthelet M.
        • Loire R.
        • Adeleine P.
        • Dayoub M.G.
        • Servan E.
        • Moreau T.
        • et al.
        Course of valvular strands in patients with stroke: cooperative study with transesophageal echocardiography.
        Am Heart J. 1998; 136: 1065-1069